![Peter Goodfellow](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Goodfellow
Vorsitzender bei Gammadelta Therapeutics Ltd.
Aktive Positionen von Peter Goodfellow
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Gammadelta Therapeutics Ltd.
![]() Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Vorsitzender | - | - |
Adaptate Biotherapeutics Ltd.
![]() Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom. | Vorsitzender | - | - |
Direktor/Vorstandsmitglied | - | - | |
Abingworth LLP
![]() Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Berater | - | - |
Karriereverlauf von Peter Goodfellow
Ehemalige bekannte Positionen von Peter Goodfellow
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GENSIGHT BIOLOGICS S.A. | Direktor/Vorstandsmitglied | 01.06.2014 | 21.06.2023 |
Independent Dir/Board Member | 01.06.2014 | 21.06.2023 | |
deCODE genetics, Inc.
![]() deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Direktor/Vorstandsmitglied | 15.09.2006 | 13.07.2010 |
GSK PLC | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1998 | - |
University of Cambridge | Corporate Officer/Principal | - | - |
Virion Biotherapeutics Ltd.
![]() Virion Biotherapeutics Ltd. BiotechnologyHealth Technology Virion Biotherapeutics Ltd. operates as a biotechnology company that develops novel therapeutics for respiratory viral infections. The firm focuses on prevention and treatment of influenza and respiratory syncytial virus. The company was founded by Nigel Dimmock and Andrew Easton in 2017 and is headquartered in Coventry, the United Kingdom. | Direktor/Vorstandsmitglied | 14.10.2017 | - |
Muscular Dystrophy Campaign Ltd. | Direktor/Vorstandsmitglied | - | - |
░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░ ░░░░░░░░░ ░░ ░░░░░░ ░░░░░░░░░ ░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Ausbildung von Peter Goodfellow
University of Oxford | Doctorate Degree |
University of Bristol | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 10 |
Island | 2 |
Niederlande | 2 |
Operativ
Director/Board Member | 7 |
Doctorate Degree | 2 |
Chairman | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 4 |
Commercial Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
GSK PLC | Health Technology |
GENSIGHT BIOLOGICS S.A. | Health Technology |
Private Unternehmen | 8 |
---|---|
deCODE genetics, Inc.
![]() deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
The Institute of Cancer Research: Royal Cancer Hospital
![]() The Institute of Cancer Research: Royal Cancer Hospital Miscellaneous Commercial ServicesCommercial Services The Institute of Cancer Research: Royal Cancer Hospital operates as a cancer research institution. The company was founded in 1909 and is headquartered in London, the United Kingdom. | Commercial Services |
Prosensa Holding NV
![]() Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
Muscular Dystrophy Campaign Ltd. | |
Gammadelta Therapeutics Ltd.
![]() Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Virion Biotherapeutics Ltd.
![]() Virion Biotherapeutics Ltd. BiotechnologyHealth Technology Virion Biotherapeutics Ltd. operates as a biotechnology company that develops novel therapeutics for respiratory viral infections. The firm focuses on prevention and treatment of influenza and respiratory syncytial virus. The company was founded by Nigel Dimmock and Andrew Easton in 2017 and is headquartered in Coventry, the United Kingdom. | Health Technology |
Adaptate Biotherapeutics Ltd.
![]() Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom. | Commercial Services |
Abingworth LLP
![]() Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Finance |
- Börse
- Insiders
- Peter Goodfellow
- Erfahrung